Skip to main content
Premium Trial:

Request an Annual Quote

Tempus Edge

Tempus has introduced Edge, a platform that gives pathologists online access to artificial intelligence models that help identify specimens with potentially significant biomarkers with a single hematoxylin and eosin-stained slide. The firm debuted Edge with a model portfolio called Tempus Histogenomics, which will include digital pathology algorithms to predict the potential of biomarkers including microsatellite instability and homologous recombination deficiency status from an H&E slide in patients whose biopsy samples are typically not sequenced.